Launch of new-age “sensor” pill

With generic competition now in the frame for the originator brand of aripiprazole in the USA, manufacturers have boldly headed where no standard pharmaceutical products have ventured before, launching a drug-device pairing that will enable clinicians to monitor...

More evidence on the risks associated with pregabalin

Respected Australian researchers have added further information that underlines growing concerns about the adverse effects associated with the widespread use of pregabalin. In a recently published study, examining 122,572 people dispensed pregabalin and also those...

Benefits of aspirin for secondary prevention fail to ARRIVE

The ARRIVE study was a LARGE randomised, double-blind, placebo-controlled, multicentre. Men aged 55 years and older or women 60 years or older and with moderate cardiovascular risk. Patients were randomly assigned (1:1) to receive enteric-coated aspirin 100 mg or...